Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Regulatory And Industry Bodies Call For Open Dialog With Policymakers

Need For Policy Intervention Highlighted During IPA’s Global Innovation Summit 2021

Executive Summary

The Indian Pharmaceutical Alliance’s recent Global Innovation Summit 2021 saw regulatory and industry bodies call for policy intervention to provide support and incentives for innovation and R&D in the Indian pharmaceutical sector. Inaugurated by the Indian prime minister Narendra Modi, the summit saw Modi invite “everyone to ideate in India, innovate in India and make in India and make for the world.”

You may also be interested in...



Generics Industry At The Forefront In War Against COVID-19 In 2021

As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.

Aurobindo’s CuraTeQ Expands Biosimilars Deal With Orion For Baltic Countries

Aurobindo’s CuraTeQ Biologics has expanded its biosimilar distribution agreement with Finnish Player Orion. After covering the Nordics, Austria, Hungary and Slovenia, the partnering companies have decided to expand to the Baltic countries, with launches slated for between 2023 and 2026.

Cipla Vice Chair Explores Lung Leadership Vision With Biosimilars Opportunities

Executive vice chairperson of Cipla Samina Hamied talks to Generics Bulletin about the company’s intention to become global lung leaders on the back of biosimilars opportunities and its inhalation assets. As well as discussing Cipla’s three-year strategy, Hamied – who is also the vice president of IPA – discusses creating a favorable regulatory and policy landscape in India. 

Topics

UsernamePublicRestriction

Register

GB151446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel